Sign in

PTX on NASDAQ

Pernix Therapeutics Holdings

Pharmaceutical company

Pernix Therapeutics was a specialty pharmaceutical business with a focus on acquiring, developing and commercializing prescription drugs primarily for the U.S. market.3 Its shares trade on NASDAQ under the symbol PTX.1 Wikipedia text CC BY-SA 4.0

Price unavailable

Last updated Oct 21, 2026.

Overview

1996Founded1

Compare with another stock.

  • TickerPTX on NASDAQ1
  • Industrypharmaceutical industry1
  • HeadquartersMorristown1
  • Websitewww.pernixtx.com
  • Incorporated inMD5
  • Business address10 North Park Place, Suite 201, Morristown, Nj 079605
  • Filer categoryNon-accelerated filer, Smaller reporting company5
  • Legal formStock Corporation4
  • LEI549300F6JPO756YOD4434
  • StatusActive4
  • LEI statusLapsed (not renewed)4
  • Registered addressC/O The Corporation Trust Incorporated, 21201 Baltimore, United States4
  • Registered withBusiness Services (Maryland Department of Assessments and Taxation), D045398884

See how the biggest companies compare on our leaderboards

Pernix Therapeutics was a specialty pharmaceutical business with a focus on acquiring, developing and commercializing prescription drugs primarily for the U.S. market.3

What it owns

What Pernix Therapeutics Holdings reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Land$07 Dec 31, 2016$572.0K7 Dec 31, 2015−100.0%
Buildings and improvements$31.0K8 Dec 31, 2017$31.0K8 Dec 31, 20160%
Machinery and equipment$495.0K8 Dec 31, 2017$622.0K8 Dec 31, 2016−20.4%
Furniture and fixtures$701.0K8 Dec 31, 2017$701.0K8 Dec 31, 20160%
Computer equipment and software$435.0K8 Dec 31, 2017$447.0K8 Dec 31, 2016−2.7%
Property and equipment, before depreciation$1.7M8 Dec 31, 2017$1.8M8 Dec 31, 2016−7.7%
Accumulated depreciation$910.0K8 Dec 31, 2017$698.0K8 Dec 31, 2016+30.4%
Property and equipment, net$752.0K8 Dec 31, 2017$1.1M8 Dec 31, 2016−31.8%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$32.8M8 Dec 31, 2017$36.4M8 Dec 31, 2016−9.8%

Intangibles and goodwill

ItemLatestA year beforeChange
Goodwill$12.1M8 Dec 31, 2017$30.6M8 Dec 31, 2016−60.5%
Finite-lived intangibles, gross$379.1M8 Dec 31, 2017$413.6M8 Dec 31, 2016−8.3%
Accumulated amortization$282.5M8 Dec 31, 2017$212.5M8 Dec 31, 2016+32.9%
Finite-lived intangibles, net$85.6M8 Dec 31, 2017$158.6M7 Dec 31, 2016−46.0%

Inventory

ItemLatestA year beforeChange
Inventory, total$5.4M8 Dec 31, 2017$7.8M8 Dec 31, 2016−30.6%
Raw materials$727.0K8 Dec 31, 2017$2.4M8 Dec 31, 2016−69.3%
Work in process$238.0K8 Dec 31, 2017$08 Dec 31, 2016
Finished goods$5.9M8 Dec 31, 2017$7.4M8 Dec 31, 2016−20.3%

The story

Pernix Therapeutics Holdings (Pernix) was a publicly traded specialty pharmaceutical company primarily focused on the sales, marketing, and development of branded pharmaceutical products. The Company marketed a portfolio of branded products, including: TREXIMET, SILENOR, a non-narcotic product indicated for the treatment of insomnia characterized by difficulties with sleep maintenance, KHEDEZLA, as well as CEDAX, an antibiotic for middle ear infections. Founded in 1996, the Company was based in Morristown, New Jersey.

In 2013, Pernix acquired Cypress Pharmaceuticals and Macoven Pharmaceuticals.

In 2014, Pernix became one of the fastest growing specialty pharmaceutical companies in the US, with an expanding CNS franchise and opportunities to branch out into adjacent therapeutic areas. Additionally, in 2014, the company completed several acquisitions including the acquisition of TREXIMET from GSK and KHEDEZLA from Osmotica. In 2013, the company completed several acquisitions of pharmaceutical companies including Cypress Pharmaceuticals, Inc., Hawthorn Pharmaceuticals, Inc., Somaxon Pharmaceuticals Inc.

On February 18, 2019, Pernix Therapeutics Holdings filed a voluntary bankruptcy petition under chapter 11 of title 11 of the United States Code, meaning that the payments on its debt obligations should be immediately paid due to the event of default. Pernix and its subsidiaries simultaneously have filed a variety of “first day” motions in order to continue their operations in ordinary course of business without interruption pending the sale of their assets in one or more going concern sales pursuant to a competitive bidding and auction process.

According to Cbonds, the overall amount of outstanding notes were equal to $254 million. Former CEO of Pernix Therapeutics, John Sedor, filed a claim in bankruptcy court for the amount of $1,534,375. John Sedor willingly and knowingly misled employees and shareholders of the company while backdoor negotiating an exit plan for Highbridge Capital Management to inflate the stock price a week before the bankruptcy was declared. This allowed all the insiders who knew of the impending Chapter 11 bankruptcy to sell their shares at a premium.

From Wikipedia’s article on Pernix Therapeutics Holdings, shared under CC BY-SA 4.0.6

Leadership

Who has led Pernix Therapeutics Holdings, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Michael Cooper Pearce2009–2013
  2. Cooper C. Collins2010–2013
  3. Douglas Drysdale2014–2016
  4. John A. Sedor2016–2018

Chair

  1. John A. Sedor2016–2018

President

  1. Michael Cooper Pearce2009–2013
  2. Cooper C. Collins2010–2013
  3. Graham G. Miao2016–2017

Chief financial officer

  1. Tracy Simmons Clifford2009–2011
  2. David Paul Becker2011–2012
  3. Sanjay S. Patel2014–2016
  4. Graham G. Miao2016–2017

Chief operating officer

  1. Terence Novak2014–2016
200020052010201520202025
Board members and other officers (27)

Former names

  • GOLF TRUST OF AMERICA INCNov 12, 1996 to Mar 11, 20105

Timeline

  1. May 11, 2016New chief executive John A. Sedor becomes CEO9
  2. Feb 7, 2014New chief executive Douglas Drysdale becomes CEO10
  3. Mar 11, 2010New chief executive Cooper C. Collins becomes CEO11
  4. Oct 27, 2009New chief executive Michael Cooper Pearce becomes CEO12
  5. 1996Founded Founded1

SEC filer profile

How Pernix Therapeutics Holdings is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARPERNIX THERAPEUTICS HOLDINGS, INC.2
  • CIK0001024126
  • Employer ID (EIN)33-07247362
  • Filer statusNon-accelerated filer<br>smaller reporting company2
  • Incorporated inMaryland2
  • Fiscal year endsDecember 312
  • Industry code (SIC)2834 Pharmaceutical Preparations2
  • Business address10 North Park Place, Suite 201, Morristown, NJ 079602
  • Phone(862) 260-84572
  • Shares outstanding14,505,848 as of Nov 6, 201844
  • Public float$40.3M as of Jun 30, 20178
  • On EDGAR sinceNov 12, 19962
  • Filings807 in all: 8-K (201), 4 (146), 10-Q (66), SC 13G/A (54), 3 (31), SC 13G (31), SC 13D/A (28), DEF 14A (21)2
    All 54 form types

    10-K (18), DEFA14A (18), SC 13D (16), UPLOAD (16), CORRESP (14), 8-K/A (12), 5 (11), S-8 (11), S-3 (9), 4/A (8), EFFECT (8), ARS (6), S-11/A (6), 424B3 (5), 425 (5), PRE 14A (5), S-3/A (5), 10-K405 (4), 10-Q/A (4), 424B5 (4), NT 10-Q (4), 10-K/A (3), 25-NSE (2), 25-NSE/A (2), 3/A (2), 424B1 (2), 8-A12B (2), 8-A12B/A (2), 8-A12G (2), CT ORDER (2), PRER14A (2), S-11 (2), S-4 (2), S-4/A (2), S-8 POS (2), 15-12B (1), 15-12G (1), 25 (1), 5/A (1), CERTNAS (1), D (1), DEFM14A (1), DEFS14A (1), FWP (1), NT 10-K (1), PREM14A (1)

  • Latest filingsAnnual report (10-K) Mar 8, 2018
    Quarterly report (10-Q) Nov 13, 2018
    Proxy statement (DEF 14A) Apr 9, 2018
    Latest 8-K (8-K) Jun 26, 2019

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44